Overview
Kynexis is a biotechnology company specializing in biomarker-guided therapeutic development for neuropsychiatric and cognitive impairment disorders. The company employs a biomarker-based approach to optimize pharmacokinetics and enable targeted therapy design in clinical trials for neuropsychiatric drugs.
More in Neurotechnology
Latest industry news
Butterfly Network's BCI Chip Licensing Deal Rattles Investors as Shares Drop Nearly 10%
2026-09-02 · Industry
Merge Labs and Butterfly Network Unite to Push Ultrasound-Based BCIs Into the Mainstream
2026-09-01 · Industry
FDA Grants CorTec Second Breakthrough Device Designation for Its Brain-Computer Interface
2026-08-31 · Policy
Aurenar Raises $5.7M to Bring Stroke Neuromodulation to the Recovery Room
2026-08-30 · Funding
Company details
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →